Anzeige
Meldung des Tages: Gold über 5.000 USD verändert die Wirtschaftlichkeit grundlegend!

Oncolytics Biotech Aktie News

Aktie
WKN:  A2JMW5 ISIN:  CA6823108759 US-Symbol:  ONCY Branche:  Biotechnologie Land:  Kanada
1,13 $
-0,11 $
-8,87%
0,9507 € 26.01.26
Depot/Watchlist
Marktkapitalisierung *
62,33 Mio. €
Streubesitz
94,71%
KGV
-3,21
Index-Zuordnung
Nasdaq Composite Index

Oncolytics Biotech News

23.05.25 - PR Newswire
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
New Data and Deal Flow Signal a Turning Point for Precision-​Driven Cancer Biotechs PR Newswire
23.05.25 - PR Newswire
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
New Data and Deal Flow Signal a Turning Point for Precision-​Driven Cancer Biotechs PR Newswire
23.05.25 - PR Newswire
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities PR Newswire
14.05.25 - PR Newswire
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum PR Newswire
06.05.25 - PR Newswire
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights PR Newswire
01.05.25 - PR Newswire
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty PR Newswire
01.05.25 - PR Newswire
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty PR Newswire
24.04.25 - PR Newswire
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-​Fighting Mechanism of Action PR Newswire
14.04.25 - PR Newswire
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz PR Newswire
14.04.25 - PR Newswire
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz PR Newswire
10.04.25 - PR Newswire
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital PR Newswire
10.04.25 - PR Newswire
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers PR ...
08.03.25 - PR Newswire
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge PR Newswire
07.03.25 - PR Newswire
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 PR Newswire
27.02.25 - PR Newswire
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire
27.02.25 - PR Newswire
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire
25.02.25 - PR Newswire
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights PR Newswire
19.02.25 - PR Newswire
Investors Eye Biotech Sector as Cancer Therapy Market Surges
Investors Eye Biotech Sector as Cancer Therapy Market Surges PR Newswire
19.02.25 - PR Newswire
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 PR Newswire
18.02.25 - PR Newswire
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer PR Newswire

Newssuche

Videos

newspaper
01:40 Uhr +0,18%
Wahnsinn! Warum Daytrader im FDAX oft verlieren
Ab Montag, dem 2. Februar börsentäglich ab 18 Uhr - FEIERABEND-​TRADING! Echte Trades auf Basis ... Mehr »